Ellen Snow - 14 Jan 2023 Form 4 Insider Report for Pear Therapeutics, Inc.

Role: Chief Accounting Officer
Signature: /s/ Stacie S. Aarestad, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 14 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 18 Jan 2023, 16:02:54 UTC
Previous filing: 18 Feb 2022
Next filing: 24 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PEARQ	Common Stock	Options Exercise	$0	+20,320	+184%	$0.000000	31,345	14 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PEARQ	Restricted Stock Units	Options Exercise	$0	-20,320	-33%	$0.000000	41,256	14 Jan 2023	Common Stock	20,320		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 11,025 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on December 30, 2022.
F2	Each restricted stock unit represents a contingent right to receive one share of PEAR common stock.
F3	The remaining restricted stock units shall vest and settle as to 33% of the shares on January 14, 2024 and 34% on January 14, 2025.